Skip to content

CeriBell, Inc. CBLL Return on assets

Return on assets at other companies

IAR
Integra LifeSciencesIART
-13%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
-47.1%-2.3pp
iRadimed logo
iRadimedIRMD
21.8%+1.0pp
Teladoc Health logo
Teladoc HealthTDOC
-5.5%-2.4pp
Kestra Medical Technologies, Ltd. Common Stock logo
Kestra Medical Technologies, Ltd. Common StockKMTS
-66.6%
Cerence Inc. logo
Cerence Inc.CRNC
-3.1%-1.5pp

Other financials

Income statement

See full
Revenue$26.5M+29.3%
Gross profit$23.1M+28.4%
Operating income-$20.7M-46.0%
Net income-$19.7M-54.5%
EPS (diluted)-$0.52-44.4%

Balance sheet

See full
Cash & equivalents$45.3M-70.5%
Total debt$22.1M+1.6%
Total equity$140.8M-22.2%
Total assets$178.1M-16.6%

Cash flow

See full
Operating cash flow-$19.3M-69.2%
CapEx$125.0K-15.5%
Free cash flow-$19.4M-68.1%

Valuation

See full
Market cap$748.61M+15.6%
Enterprise value$725.47M+40.7%
P/S7.9×-1.2×

Profitability

See full
Gross margin87.7%+0.5pp
Operating margin-68.3%+5.5pp
Net margin-63.5%+1.0pp
FCF margin-52%-1.4pp

Returns & leverage

See full
Return on equity-37.5%
Debt / equity0.2×0.0×
Current ratio10.4×-6.9×

Where this comes from

Calculated from CeriBell, Inc.’s reported figures.

Based on trailing twelve months.

The official record: CeriBell, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about CeriBell, Inc.'s return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CeriBell, Inc.'s return on assets?
CeriBell, Inc. (CBLL) reported return on assets of -30.8% in Q1 2026.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.